Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Price Target at $60.86

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $60.8571.

KNSA has been the topic of several research analyst reports. Citigroup lifted their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, May 6th. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Canaccord Genuity Group upped their target price on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $48.38 on Friday. The stock has a market capitalization of $3.72 billion, a price-to-earnings ratio of 53.76 and a beta of 0.17. Kiniksa Pharmaceuticals International has a 1-year low of $26.27 and a 1-year high of $59.87. The company has a 50 day moving average price of $49.94 and a 200 day moving average price of $45.36.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company had revenue of $214.27 million during the quarter, compared to analysts’ expectations of $206.11 million. During the same period last year, the company posted $0.11 earnings per share. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares of the company’s stock, valued at $3,524,611.33. The trade was a 47.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Michael R. Megna sold 6,625 shares of the firm’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the sale, the chief accounting officer directly owned 27,418 shares in the company, valued at approximately $1,280,146.42. This represents a 19.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 653,301 shares of company stock valued at $34,046,073 in the last three months. 51.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP raised its stake in shares of Kiniksa Pharmaceuticals International by 281.9% in the third quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock valued at $3,028,000 after purchasing an additional 57,566 shares in the last quarter. Aberdeen Group plc acquired a new stake in Kiniksa Pharmaceuticals International during the third quarter worth $6,163,000. Fisher Asset Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 176.1% during the third quarter. Fisher Asset Management LLC now owns 282,288 shares of the company’s stock worth $10,961,000 after buying an additional 180,029 shares in the last quarter. Essex Investment Management Co. LLC increased its holdings in Kiniksa Pharmaceuticals International by 44.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company’s stock valued at $9,603,000 after buying an additional 75,864 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after buying an additional 49,802 shares during the period. 53.95% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.